×
About 16,097 results

ALLMedicine™ Mesothelioma Center

Research & Reviews  7,765 results

Incidence of mesothelioma and asbestosis by occupation in a diverse workforce.
https://doi.org/10.1002/ajim.23245
American Journal of Industrial Medicine; DeBono NL, Warden H et. al.

Apr 9th, 2021 - We sought to characterize detailed patterns of mesothelioma and asbestosis incidence in the workforce as part of an occupational disease surveillance program in Ontario, Canada. The Occupational Disease Surveillance System (ODSS) cohort was establ...

Understanding the palliative care needs and experiences of people with mesothelioma and...
https://doi.org/10.1177/02692163211007379
Palliative Medicine; Harrison M, Gardiner C et. al.

Apr 8th, 2021 - People with mesothelioma and their families have palliative care needs throughout the relatively short trajectory of their illness. To describe the palliative care needs and experiences of people with mesothelioma and their family carers. Integrat...

Utility of SOX6 and DAB2 for the Diagnosis of Malignant Mesothelioma.
https://doi.org/10.1097/PAS.0000000000001712
The American Journal of Surgical Pathology; Naso JR, Cheung S et. al.

Mar 30th, 2021 - The separation of malignant mesothelioma from non-small cell lung carcinomas can be a difficult problem. Sex-determining region Y box 6 (SOX6) and disabled homolog 2 (DAB2) have recently been proposed as sensitive/specific markers of mesothelial l...

Clinicopathological characteristics of primary peritoneal epithelioid mesothelioma of c...
https://doi.org/10.1097/MD.0000000000025264
Medicine Du XM, Wei YP et. al.

Mar 25th, 2021 - Primary peritoneal epithelioid mesothelioma of clear cell type is an extremely rare entity composed of clear cytoplasm. It is challenging to diagnose because of the morphological resemblance to clear cell tumor. A 69-year-old male patient had swol...

The therapeutic implications of the genomic analysis of malignant pleural mesothelioma.
https://doi.org/10.1038/s41467-021-22142-y 10.1016/j.jtho.2015.11.005 10.1200/JCO.2017.76.6394 10.1038/ng.855 10.1038/ng.3520 10.1158/2159-8290.CD-18-0804 10.1016/S0140-6736(20)32714-8 10.1056/NEJMoa1714448 10.1200/JCO.2016.71.3230 10.1200/JCO.2018.36.15_suppl.8515
Nature Communications; Zauderer MG

Mar 23rd, 2021 - The therapeutic implications of the genomic analysis of malignant pleural mesothelioma.|2021|Zauderer MG,|therapeutic use,genetics,methods,administration & dosage,drug therapy,genetics,drug therapy,genetics,administration & dosage,drug therapy,gen...

see more →

Guidelines  39 results

Durvalumab Added to Standard Chemotherapy Improved Overall Survival in Patients With Malignant Pleural Mesothelioma
https://ascopost.com/news/june-2020/durvalumab-added-to-standard-chemotherapy-improved-os-in-patients-with-malignant-pleural-mesothelioma/

May 31st, 2020 - Data from clinical efficacy and biomarker analyses conducted for the single-arm phase II PrE0505 study of the initial treatment of patients with malignant pleural mesothelioma were presented by Patrick Forde, MB, BCh, and colleagues during the Lun...

Ramucirumab-gemcitabine combination confers OS benefit in malignant pleural mesothelioma
https://www.healio.com/hematology-oncology/lung-cancer/news/online/{2cadd0d4-adb1-4d44-8ef3-4f1f2b3fa922}/ramucirumab-gemcitabine-combination-confers-os-benefit-in-malignant-pleural-mesothelioma

May 29th, 2020 - The addition of ramucirumab to gemcitabine significantly improved survival among patients with malignant pleural mesothelioma, according to randomized phase 2 study results presented during the ASCO20 Virtual Scientific Program.

Malignant Mesothelioma Treatment (Adult) (PDQ®)–Health Professional Version
https://www.cancer.gov/types/mesothelioma/hp/mesothelioma-treatment-pdq

Sep 24th, 2019 - Malignant mesothelioma treatment may include surgery, radiation therapy, and chemotherapy. Get detailed information about the diagnosis and treatment of newly diagnosed and recurrent malignant mesothelioma in this summary for clinicians.

FDA Approves the NovoTTF-100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma
https://www.novocure.com/fda-approves-the-novottf-100ltm-system-in-combination-with-chemotherapy-for-the-treatment-of-malignant-pleural-mesothelioma/

May 22nd, 2019 - Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved the NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally adv...

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND—A Double-Blind, Randomized, Phase II Study
https://doi.org/10.1200/JCO.2018.79.0543

Feb 19th, 2019 - Inhibition of focal adhesion kinase has been shown to selectively kill mesothelioma cells that express low levels of moesin-ezrin-radixin-like protein (merlin). On this basis, we designed a randomized, phase II trial to investigate whether defacti...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  8,067 results

Incidence of mesothelioma and asbestosis by occupation in a diverse workforce.
https://doi.org/10.1002/ajim.23245
American Journal of Industrial Medicine; DeBono NL, Warden H et. al.

Apr 9th, 2021 - We sought to characterize detailed patterns of mesothelioma and asbestosis incidence in the workforce as part of an occupational disease surveillance program in Ontario, Canada. The Occupational Disease Surveillance System (ODSS) cohort was establ...

Understanding the palliative care needs and experiences of people with mesothelioma and...
https://doi.org/10.1177/02692163211007379
Palliative Medicine; Harrison M, Gardiner C et. al.

Apr 8th, 2021 - People with mesothelioma and their families have palliative care needs throughout the relatively short trajectory of their illness. To describe the palliative care needs and experiences of people with mesothelioma and their family carers. Integrat...

Utility of SOX6 and DAB2 for the Diagnosis of Malignant Mesothelioma.
https://doi.org/10.1097/PAS.0000000000001712
The American Journal of Surgical Pathology; Naso JR, Cheung S et. al.

Mar 30th, 2021 - The separation of malignant mesothelioma from non-small cell lung carcinomas can be a difficult problem. Sex-determining region Y box 6 (SOX6) and disabled homolog 2 (DAB2) have recently been proposed as sensitive/specific markers of mesothelial l...

Clinicopathological characteristics of primary peritoneal epithelioid mesothelioma of c...
https://doi.org/10.1097/MD.0000000000025264
Medicine Du XM, Wei YP et. al.

Mar 25th, 2021 - Primary peritoneal epithelioid mesothelioma of clear cell type is an extremely rare entity composed of clear cytoplasm. It is challenging to diagnose because of the morphological resemblance to clear cell tumor. A 69-year-old male patient had swol...

The therapeutic implications of the genomic analysis of malignant pleural mesothelioma.
https://doi.org/10.1038/s41467-021-22142-y 10.1016/j.jtho.2015.11.005 10.1200/JCO.2017.76.6394 10.1038/ng.855 10.1038/ng.3520 10.1158/2159-8290.CD-18-0804 10.1016/S0140-6736(20)32714-8 10.1056/NEJMoa1714448 10.1200/JCO.2016.71.3230 10.1200/JCO.2018.36.15_suppl.8515
Nature Communications; Zauderer MG

Mar 23rd, 2021 - The therapeutic implications of the genomic analysis of malignant pleural mesothelioma.|2021|Zauderer MG,|therapeutic use,genetics,methods,administration & dosage,drug therapy,genetics,drug therapy,genetics,administration & dosage,drug therapy,gen...

see more →

News  211 results

Malignant Pleural Mesothelioma Clinical Practice Guidelines (SEOM, 2021) 
https://reference.medscape.com/viewarticle/946415

Mar 1st, 2021 - Guidelines on malignant pleural mesothelioma were published on February 4, 2021 by the Spanish Society of Medical Oncology in Clinical Guides in Oncology.[1] Diagnosis and Staging Genomic studies are not recommended in routine clinical practice bu...

Gemcitabine Maintenance After First-Line Chemo Prolongs PFS in Malignant Mesothelioma
https://www.medscape.com/viewarticle/945372

Feb 7th, 2021 - NEW YORK (Reuters Health) - Gemcitabine maintenance therapy after first-line chemotherapy significantly prolonged progression-free survival (PFS) in patients with malignant mesothelioma, according to results of the Dutch NVALT19 trial. "Almost all...

Nivolumab Improves Survival in Relapsed Mesothelioma
https://www.medscape.com/viewarticle/945049

Jan 31st, 2021 - In the first ever placebo-controlled phase 3 trial in patients with relapsed mesothelioma, immunotherapy with nivolumab (Opdivo) significantly improved both overall survival (OS) and progression-free survival (PFS).   The CONFIRM trial involved 33...

Pre-COVID PHE Statistics Show Improving Cancer Survival Rates
https://www.staging.medscape.com/viewarticle/940661

Nov 9th, 2020 - Public Health England (PHE) has published new statistics which show improved survival in most cancers. The data cover a pre-pandemic period so the impact of recent delays in diagnosis and treatment won't be known for some time. The new figures sho...

Pre-COVID PHE Statistics Show Improving Cancer Survival Rates
https://www.medscape.com/viewarticle/940661

Nov 9th, 2020 - Public Health England (PHE) has published new statistics which show improved survival in most cancers. The data cover a pre-pandemic period so the impact of recent delays in diagnosis and treatment won't be known for some time. The new figures sho...

see more →

Patient Education  13 results see all →